Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | CCR8 | P51685 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444381 | 0.76 | CES1 (0.47) | KMT2ATDP1KDM4ELMNAPOLB | |
| SCHEMBL8304026 | 0.75 | CTNNB1 (0.52) | CTNNB1WNT3AKMT2ATDP1KDM4E | |
| SCHEMBL28561412 | 0.73 | CTNNB1 (0.55) | CTNNB1WNT3AKMT2ATDP1KDM4E | |
| SCHEMBL2890937 | 0.71 | KMT2A (0.63) | CTNNB1WNT3AKMT2ATDP1KDM4E | |
| Urea SCHEMBL28595140 | 0.67 | KMT2A (0.57) | CTNNB1WNT3AKMT2ATDP1KDM4E | |
| SCHEMBL28270533 | 0.66 | CTNNB1 (0.52) | CTNNB1WNT3AKMT2AKDM4ELMNA | |
| SCHEMBL24579553 | 0.64 | P2RX7 (0.42) | CTNNB1WNT3AKMT2ATDP1KDM4E | |
| SCHEMBL440808 | 0.64 | — | — | |
| Dipyridyl SCHEMBL28995265 | 0.63 | KDM4E (0.70) | KMT2ATDP1KDM4ELMNAP4HTM | |
| SCHEMBL28567909 | 0.63 | KMT2A (0.48) | CTNNB1WNT3AKMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103313599-B | Substituted 4- (arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD. (IN) | 2016-03-23 | — | — | CN | disclosed |
| US-9090633-B2 | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2015-07-28 | — | — | US | disclosed |
| EP-2648509-B1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-04-29 | — | — | EP | disclosed |
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| EP-2648509-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-10-16 | — | — | EP | disclosed |
| CN-103313599-A | Substituted 4- (arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD | 2013-09-18 | — | — | CN | disclosed |
| WO-2012077135-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | SELENOI, VHL, DPYD | CTNNB1 624/4885WNT3A 1391/4885KMT2A 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.